Clinical Trials Browser

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT06917079 2026-03-23

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Phase 1 Recruiting

387 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT06246110 2025-11-12

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

Phase 2 Recruiting

70 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05431270 2025-01-31

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Phase 1/2 Recruiting

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04999761 2024-09-25

AB122 Platform Study

Phase 1 Recruiting

917 enrolled

GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

NCT06413992 2024-05-14

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Phase 2 Recruiting

117 enrolled

Gynecologic

Neoplasm Metastasis, Recurrence, Endometrial Neoplasms

Clinical Trials

FRAmework-01

A Study of ASP3082 in Adults With Advanced Solid Tumors

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

WOLF

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

SUNRAY-01

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

AB122 Platform Study

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer